Drug approved for patients with ALK-positive, early-stage cancer who undergo surgery to remove their tumor
Findings seen among patients with resected ALK-positive non-small cell lung cancer
Of those newly eligible under 2021 criteria, 2,063,840 were aged 50 to 54 years and 4,020,879 had 20 to 29-pack-year smoking history
Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab
Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy
For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery
HFJV under general anesthesia as safe as spontaneous respiration under moderate sedation for percutaneous lung ablation
